Trial Profile
A Phase 2a, Randomized, Double-blind, Sponsor Unblinded, Placebo-controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Subjects With Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2021
Price :
$35
*
At a glance
- Drugs Anrukinzumab (Primary)
- Indications Ulcerative colitis
- Focus Biomarker; Pharmacodynamics
- Sponsors Pfizer
- 15 Oct 2013 Primary endpoint 'Fecal-calprotectin-levels' has not been met.
- 15 Oct 2013 Results presented at the 21st United European Gastroenterology Week.
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.